Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multifunctional exosomes inhibiting autophagy ameliorate immune tolerance in non-small cell lung cancer

ABSTRACT: The modulation of tumor autophagy to enhance antitumor immunity has garnered significant attention, underscoring its critical role in cancer immunotherapy. However, advanced strategies for precise autophagy-regulating drug delivery remain a pressing need. Here, we introduce a targeted exosome-based drug delivery system capable of simultaneously loading antibodies and nucleic acid drugs while ensuring their accurate release in the tumor microenvironment (TME). We developed a dual-stimulation electroporation system integrating nanosecond electric pulses and ultrasound to enhance exosome production, yielding IL-7 mRNA-enriched exosomes overexpressing CD64 receptors for efficient anti-PD-L1 antibody capture. These multifunctional autophagy-inhibiting and immunomodulatory exosomes (AI-Exos) are designed to inhibit autophagy and modulate immune responses in lung cancer. Upon delivery to the tumor site, AI-Exos mediate the enzymatic cleavage of peptide bonds to release IL-7 mRNA. This process induces autophagy suppression and restores MHC-I expression, which synergizes with anti-PD-L1 immune checkpoint inhibition to overcome acquired drug resistance and enhance antitumor efficacy. In conclusion, this study proposes an innovative methodology utilizing engineering exosomes for the co-delivery of protein antibodies and genetic materials. This approach establishes a promising strategy to advance cancer immunotherapy through targeted autophagy modulation.

ORGANISM(S): Mus musculus

PROVIDER: GSE298562 | GEO | 2026/02/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Multifunctional exosomes inhibiting autophagy ameliorate immune tolerance in non-small cell lung cancer II

Project description:The modulation of tumor autophagy to enhance antitumor immunity has garnered significant attention, underscoring its critical role in cancer immunotherapy. However, advanced strategies for precise autophagy-regulating drug delivery remain a pressing need. Here, we introduce a targeted exosome-based drug delivery system capable of simultaneously loading antibodies and nucleic acid drugs while ensuring their accurate release in the tumor microenvironment (TME). We developed a dual-stimulation electroporation system integrating nanosecond electric pulses and ultrasound to enhance exosome production, yielding IL-7 mRNA-enriched exosomes overexpressing CD64 receptors for efficient anti-PD-L1 antibody capture. These multifunctional autophagy-inhibiting and immunomodulatory exosomes (AI-Exos) are designed to inhibit autophagy and modulate immune responses in lung cancer. Upon delivery to the tumor site, AI-Exos mediate the enzymatic cleavage of peptide bonds to release IL-7 mRNA. This process induces autophagy suppression and restores MHC-I expression, which synergizes with anti-PD-L1 immune checkpoint inhibition to overcome acquired drug resistance and enhance antitumor efficacy. In conclusion, this study proposes an innovative methodology utilizing engineering exosomes for the co-delivery of protein antibodies and genetic materials. This approach establishes a promising strategy to advance cancer immunotherapy through targeted autophagy modulation.

2026-02-18 | GSE298789 | GEO

3D-ASC-Exos as a novel drug carrier for glioma treatment

Project description:It is known that antler stem cell extract has an inhibitory effect on glioma growth. Therefore, it is speculated that antler stem cell-derived exosomes (ASC-Exos) can be used as a new drug carrier for the treatment of glioma. Due to the limitation of exosome sources, we constructed a 3D culture system to harvest more exosomes. In this experiment, compared with the 2D-ASC-Exos obtained from the traditional 2D culture, the 3D-ASC-Exos obtained from our constructed 3D culture system were concentrated nearly 30 times in the culture medium volume, which was more convenient for subsequent purification. The two forms of ASC-Exos had similar morphologies and surface markers, but 3D-ASC-Exos were enriched with more miRNAs related to tumor suppression. In vitro experiments demonstrated that 3D-ASC-exosomes loaded with temozolomide (TMZ) inhibited the proliferation, migration and invasion abilities of glioma cells and promoted the apoptosis of glioma cells. The vivo tumor-bearing mouse model demonstrated that 3D-ASC-Exos loaded with TMZ exerted tumor-suppressive effects by inhibiting tumor growth and promoting tumor apoptosis. Meanwhile, the treatment with 3D-ASC-Exos loaded with TMZ caused no damage to the various tissues and organs of mice compared with the TMZ group. In conclusion, 3D-ASC-Exos can be used as a novel drug carrier for the treatment of glioma.

2025-12-02 | GSE305022 | GEO

The effect of high or low fat diet on the miRNA composition of exosomes derived from adipose tissue

Project description:Exosomes are nanosized extracellular vesicles with lipid bilayer membranes and contain various contents, including lipids, miRNAs and proteins, all of which are widely involved in signaling pathways and genetic information processes. Exosomes derived from adipose tissues (AT-Exos) have been identified as a crucialmedium in the transmission of information from adipose tissue to itself and to other organs, including exosomes derived from inguinal white adipose tissue (iWAT-Exos), visceral white adipose tissue (vWAT-Exos) and brown adipose tissue (BAT-Exos). Here we reported that dietary conditions and tissue origins of exosome can affect the composition and function of miRNAs in AT-Exos, mainly including lipid metabolism and inflammatory signaling pathways associated with metabolic imbalance.

2024-04-25 | GSE264481 | GEO

Reinforced immunotherapy of M1 macrophage-derived exosomes with CEL on TNBC via regulating macrophage functions

Project description:Triple-negative breast cancer (TNBC) demonstrates poor prognosis due to its heterogeneity-related biological barrier, immunosuppressive tumor microenvironment (TME) and escape of cancer cells on immune surveillance. Exosomes are membrane-encased vehicles with properties of inter- and intra-cellular communication and regulation for therapeutic use, even as drug vehicles. M1 macrophage-derived exosomes (M1-Exos) can communicate with adjacent M2 macrophages and reprogram them to M1 subtypes to reshape TME. Celastrol (CEL) is a highly promising natural antitumor drug and plays an important role in immunotherapy but with high toxicity and low water solubility.

2026-02-27 | GSE320206 | GEO

RNA-seq of A375 cells treated with I-BET726 alone and sequential combination of I-BET726 and Oxaliplatin

Project description:Sequential therapy is a promising approach to enhance antitumor efficacy; however, rational design of sequential drug treatments remains challenging. Here, we applied an AI framework, AlphaTherapy, to identify a specific sequential drug combination of I-BET726 and Oxaliplatin that exhibits antitumor effects in melanoma (A375 cells). To investigate the molecular mechanisms underlying the antitumor activity of this combination, gene expression was profiled by RNA sequencing (RNA-seq) after treatment.

2025-12-22 | GSE306207 | GEO

Exosomal subgroups isolated from MSCs by tangential flow filtration combined with size exclusion chromatography reals distinct molecular properties and functions

Project description:Here, by using TFF-SEC system to separate exosomal subgroups, our study provides an industrial-scale method for the scalable production of MSC exosomes with specific functions. The two exosome subgroups, S1-Exos and S2-Exos, differ in their biogenesis, characterization, and content of cargos, resulting in variations in their biological functions. Although stem cells have been widely used in clinical research and therapy, ineffectiveness or lack of stability still exists (26140604, 26908143). In spite of the well-known advantages of MSCs-Exos in clinical applications, our research introduces a new concept that involves leveraging distinct subpopulations of MSC exosomes for targeted therapeutic interventions in specific diseases.

2025-01-15 | GSE256371 | GEO

Gene expression changes were assessed in tumor cells treated with epigenetic inhibitors and after drug withdrawal

Project description:Sequential therapy is a promising strategy to enhance antitumor efficacy; however, the rational design of sequential drug treatments remains challenging. Here, we introduce an AI framework, AlphaTherapy, which can design sequential drug combinations for cancer treatment. Analysis of AlphaTherapy-predicted combinations and large-scale in vitro validation revealed that the first drug in effective anti-tumor combinations often targets transcription, particularly epigenetic inhibitors. To investigate how epigenetic drugs enhance the efficacy of subsequent treatments, RNA-seq was performed on tumor cells treated with epigenetic inhibitors followed by drug withdrawal to assess gene expression changes.

2025-12-22 | GSE306072 | GEO

Plasma-derived exosomes boost the healing of irradiated wound by regulating cell proliferation and ferroptosis

Project description:Ionizing radiation (IR) therapy for malignant tumors can damage adjacent tissues, leading to severe wound complications. Plasma-derived exosome treatment has recently emerged as a safe and impactful cell-free therapy. Herein, we aimed to determine whether plasma-derived exosomes could improve the healing of post-radiation wound. Rat plasma-derived exosomes (RP-Exos) were locally injected on cutaneous wounds created on the backs of irradiated rats and boosted the healing process as well as the deposition and remodeling of the extracellular matrix with collagen formation. Subsequently, the effects of RP-Exos were further evaluated on irradiated fibroblasts in vitro. The results suggested that exosomes promoted fibroblast proliferation, migration, cell cycle progression, and cell survival. Moreover, transcriptome sequencing, analysis, and quantitative polymerase chain reaction validation were performed to identify the underlying molecular mechanisms. RP-Exos enhanced the expression of cell proliferation and radioresistance-related genes, and yet downregulated ferroptosis pathway in irradiated fibroblasts. Inhibition of ferroptosis by RP-Exos was further confirmed through colorimetric assay, fluorescence probe and flow cytometry in ferroptosis-induced fibroblasts. Our results suggest that RP-Exos regulate cell proliferation and ferroptosis in radiated fibroblasts, thereby boosting the healing of radiated wounds. These findings support plasma-derived exosomes as a potential therapeutic method for post-radiation wound complications.

2021-06-30 | GSE162722 | GEO

Exosome release is regulated by mTORC1 via a Rab27A-dependent mechanism

Project description:Exosomes are small membrane-bound vesicles released into extracellular spaces by many types of cells. These nanovesicles carry proteins, mRNA and miRNA and are involved in cell waste management and intercellular communication. In the present study we show that exosome release, which leads to net loss of cellular membrane and protein content, is negatively regulated by mechanistic target of rapamycin complex 1 (mTORC1). We find that in cells and animal models exosome release is inhibited by sustained activation of mTORC1, leading to intracellular accumulation of CD63-positive exosome precursors. Inhibition of mTORC1 by rapamycin or nutrient and growth factor deprivation stimulates exosome release, which occurs concomitantly with autophagy. The drug-stimulated release is blocked by siRNA-mediated downregulation of small GTPase Rab27A. Analysis of the cargo content in exosomes released from rapamycin treated cells reveals that inhibition of mTORC1 does not alter its protein and miRNA profiles. These observations demonstrate that exosome release, like autophagy, is negatively regulated by mTORC1 in response to changes in nutrient and growth factor conditions

2019-03-05 | GSE114235 | GEO

Data in support of proteomics of EVs ámd mimetic vesicles from

Project description:Exosomes (EXOs) are a biological subset of extracellular vesicles of 50-200 nm in size which are released by most cells upon fusion of multivehicular bodies with plasma membrane.Mimetic-Nanovesicles (M-NVs) have higher yield compare to exosomes. In addition, M-NVs can untangle the difficulties associated with the isolation and purification of cell culture exosomes. M-NVs is consist of membranouslipid bilayer which could be derived from extrusion of cells through filter membrane. Several studies have used M-NVs for therapeutic delivery of genetic materials and drug. The proteomic content of these vesicles with regard to protein identities and post-translational modifications remain uncharacterized and proteomic data is presented in this dataset.

2022-01-05 | PXD010539 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data